Tevimbra (tislelizumab-jsgr)

P1/2, N=344, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2025 --> Apr 2026 | Trial primary completion date: Aug 2025 --> Apr 2026

P1, N=200, Recruiting, BeiGene | Active, not recruiting --> Recruiting | N=37 --> 200 | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026

The combination of Tislelizumab and Sorafenib demonstrates promising antitumor activity in the first-line treatment of hepatocellular carcinoma, with a relatively high objective response rate (ORR) and acceptable safety profile. Baseline CTC PD-L1 positivity can serve as a predictive marker for selecting hepatocellular carcinoma patients for PD-1/PD-L1 blockade therapy, and dynamic measurement of CTC changes can be used to monitor treatment efficacy.

P3, N=300, Recruiting, Sun Yat-sen University

P1, N=177, Recruiting, BeiGene | Not yet recruiting --> Recruiting

P3, N=123, Recruiting, BeiGene | Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Sep 2024 --> Feb 2026

P2, N=28, Not yet recruiting, Shanghai Zhongshan Hospital

P2, N=50, Recruiting, Beijing Tongren Hospital

P2, N=33, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

P2, N=28, Recruiting, Fondazione Italiana Linfomi - ETS | Trial completion date: Apr 2029 --> Nov 2029 | Trial primary completion date: Apr 2027 --> Nov 2027

P1/2, N=344, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2026 --> Aug 2025 | Trial primary completion date: Mar 2026 --> Aug 2025

In China, tislelizumab plus chemotherapy is a cost-effective first-line therapy for unresectable GC/GEJC in both ITT and TAP ≥ 5% subgroups. In the US, tislelizumab plus chemotherapy is not cost-effective.

P2, N=45, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Oct 2025 | Trial primary completion date: Sep 2022 --> Aug 2024

P2, N=100, Recruiting, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

P2, N=70, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Oct 2024

P=N/A, N=50, Not yet recruiting, Guiping People's Hospital

P2, N=160, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting

P2, N=30, Recruiting, Peking University Cancer Hospital & Institute | Not yet recruiting --> Recruiting

P2, N=20, Recruiting, Zhejiang Cancer Hospital | Not yet recruiting --> Recruiting

P3, N=430, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=180, Not yet recruiting, Fudan University

P1/2, N=71, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2024

P=N/A, N=1500, Recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=28, Active, not recruiting, Qilu Hospital of Shandong University | Recruiting --> Active, not recruiting | Trial primary completion date: May 2024 --> Dec 2024

P2, N=60, Recruiting, The First Affiliated Hospital with Nanjing Medical University

P2, N=144, Not yet recruiting, Ruijin Hospital

In the treatment of locally advanced NPC, a randomized phase III study showed equivalence of induction (ICT) and adjuvant therapy (AT; NCT03306121). PD-1 inhibitors have become established in the palliative therapy of NPC in recent years and could now also play an increasing role in curation: the phase III study "Dipper" showed a significantly better 3‑year event-free survival in patients adjuvantly treated with camrelizumab versus placebo after IT and definitive platinum-containing chemoradiotherapy (dRCT; 89% vs. 80%; NCT03427827). The phase III study "Beacon" showed complete remission in 30.5% of patients after IT with gemcitabine/cisplatin and the PD‑1 inhibitor tislelizumab (three cycles), a rate almost twice as high as with gemcitabine/cisplatin alone (NCT05211232). Intensification of dRCT in NPC using EGFR and VEGF inhibitors appears promising (NCT04447326). Abstracts on salivary gland and nasal and sinus cancers emphasize the importance of targeted therapies. In anaplastic thyroid carcinoma, the combination of a PD‑1 inhibitor and a CTLA4 inhibitor showed a 50% response.

P2, N=20, Not yet recruiting, Fujian Cancer Hospital

P2, N=114, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2025 --> Nov 2025

P2, N=200, Not yet recruiting, Peking University Shenzhen Hospital

OS subgroup analysis showed comparable treatment effect by TAP score at 10% cutoff, CPS at cutoff 10, and TC score at 1% cutoff. TAP score and CPS at these cutoffs exhibited substantial concordance. Results indicate that the quicker, visually estimated TAP score and CPS may be interchangeable for clinical measurement of PD-L1 expression in patients with ESCC.

P1, N=74, Recruiting, Peking University

P1, N=122, Terminated, Novartis Pharmaceuticals | Trial completion date: Jan 2025 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Sep 2024; The decision of early termination was made due to business reasons, and was not based on any safety concerns for any of the treatment combinations.

P2, N=34, Recruiting, Wuhan Union Hospital, China

P1/2, N=320, Not yet recruiting, LaNova Medicines Limited

P=N/A, N=74, Not yet recruiting, Southwest Hospital, China

P4, N=180, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

P2, N=33, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University

P2, N=46, Not yet recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital

P2, N=36, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P1, N=92, Not yet recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital

P1, N=26, Not yet recruiting, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital); The Tenth Affiliated Hospital, Southern Medical University(Do